Di- and triterpenoids from Tripterygium wilfordii

New secondary metabolites from the endophytic fungus Aspergillus sp. from Tripterygium wilfordii

One new 3,5-dimethylorsellinic acid (DMOA)-based meroterpenoid (1), one prenylated tryptophan derivative (2), together with ten known compounds (3-12) were isolated from the endophytic fungus Aspergillus sp. from Tripterygium wilfordii. Their structures and absolute configurations were determined by NMR spectroscopic data, HRESIMS data, UV and IR data as well as electronic circular dichroism (ECD) calculation. In structure, compound 1 was a rare example of DMOA-based meroterpenoid with a cis-fused C/D ring system, and compound 2 possessed an unusual (E)-oxime group. In bioactivity, the lovastatin analogues 5, 6, 9 and 10 showed potential immunosuppressive activity against anti-CD3/anti-CD28 monoclonal antibodies (mAbs)-irritated murine splenocytes proliferation, with IC₅₀ values ranging from (5.30 ± 0.51) μM to (16.51 ± 1.62) μM.

Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol

BACKGROUND

Celastrol is a novel anti-tumor agent. Ways to further enhance this effect of celastrol has attracted much research attention.

METHODS AND RESULTS

Here, we report that celastrol treatment can elevate miR-223 in human breast cancer cell line MCF-7 and prostate cancer PC3. Down-regulating miR-223 could increase the number of viable cells, yet it further reduced viable cells in samples that were treated by celastrol; up-regulation of miR-223 displayed opposite effects. Celastrol's miR-223 induction might be due to NF-κB inhibition and transient mTOR activation: these two events occurred prior to miR-223 elevation in celastrol-treated cells. NF-κB inhibitor, like celastrol, could induce miR-223; the induction of miR-223 by NF-κB inhibitor or celastrol was reduced by the use of mTOR inhibitor. Finally and interestingly, miR-223 also could affect NF-κB and mTOR and the effects were different between cells treated or not treated with celastrol, thus providing an explanation for differing effects of miR-223 alteration on cellular viability in the presence of celastrol or not.

CONCLUSIONS

For the first time, we disclose that celastrol could induce miR-223 in breast and prostate cancer cells, and that inhibiting miR-223 could further reduce the living cells in celastrol-treated cancer cell lines. We thus provide a novel way to increase celastrol's anti-cancer effects.